Collplant Biotechnologies Stock Today
| CLGN Stock | USD 5.41 0.01 0.19% |
Performance4 of 100
| Odds Of DistressLess than 11
|
Collplant Biotechnologies is selling at 5.41 as of the 25th of April 2024; that is 0.19% increase since the beginning of the trading day. The stock's open price was 5.4. Collplant Biotechnologies has less than a 11 % chance of experiencing some financial distress in the next two years of operation, but did not have a good performance during the last 90 trading days. Equity ratings for Collplant Biotechnologies are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 26th of March 2024 and ending today, the 25th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 30th of January 2018 | Category Healthcare | Classification Health Care |
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel. The company has 11.45 M outstanding shares of which 10.83 K shares are currently shorted by private and institutional investors with about 1.29 trading days to cover. More on Collplant Biotechnologies
Moving against Collplant Stock
| 0.61 | ENVB | Enveric Biosciences Financial Report 20th of May 2024 | PairCorr |
| 0.55 | ELEV | Elevation Oncology Earnings Call This Week | PairCorr |
| 0.54 | VKTX | Viking Therapeutics Potential Growth | PairCorr |
| 0.5 | BMY | Bristol Myers Squibb Earnings Call Today | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 22nd of May 2024
Collplant Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Collplant Biotechnologies' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Collplant Biotechnologies or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO Director | Yehiel Tal | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Collplant Biotechnologies report their recommendations after researching Collplant Biotechnologies' financial statements, talking to executives and customers, or listening in on Collplant Biotechnologies' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Collplant Biotechnologies. The Collplant consensus assessment is calculated by taking the average forecast from all of the analysts covering Collplant Biotechnologies. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators related to Collplant Biotechnologies' liquidity, profitability, solvency, and operating efficiency, Collplant Biotechnologies is not in a good financial situation at this time. It has a very high odds of going through financial crisis in May. Financial strength of Collplant Biotechnologies is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Collplant Biotechnologies' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Collplant Biotechnologies' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Collplant Biotechnologies' financial leverage. It provides some insight into what part of Collplant Biotechnologies' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Collplant Biotechnologies (CLGN) is traded on NASDAQ Exchange in USA. It is located in Weizmann Science Park, Rehovot, Israel, 7670104 and employs 75 people. Collplant Biotechnologies is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 61.85 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Collplant Biotechnologies's market, we take the total number of its shares issued and multiply it by Collplant Biotechnologies's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Collplant Biotechnologies conducts business under Biotechnology sector and is part of Health Care industry. The entity has 11.45 M outstanding shares of which 10.83 K shares are currently shorted by private and institutional investors with about 1.29 trading days to cover.
Collplant Biotechnologies currently holds about 36.29 M in cash with (2.76 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.27.
Check Collplant Biotechnologies Probability Of Bankruptcy
Ownership AllocationCollplant Biotechnologies retains a total of 11.45 Million outstanding shares. Collplant Biotechnologies shows 10.1 percent of its outstanding shares held by insiders and 12.23 percent owned by other corporate entities. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check Collplant Ownership Details
Collplant Stock Price Odds Analysis
Contingent on a normal probability distribution, the odds of Collplant Biotechnologies jumping above the current price in 90 days from now is about 28.39%. The Collplant Biotechnologies probability density function shows the probability of Collplant Biotechnologies stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Collplant Biotechnologies has a beta of 0.0666 suggesting as returns on the market go up, Collplant Biotechnologies average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Collplant Biotechnologies will be expected to be much smaller as well. Additionally, collplant Biotechnologies has an alpha of 0.0528, implying that it can generate a 0.0528 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
Based on a normal probability distribution, the odds of Collplant Biotechnologies to move above the current price in 90 days from now is about 28.39 (This Collplant Biotechnologies probability density function shows the probability of Collplant Stock to fall within a particular range of prices over 90 days) .
Collplant Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Collplant Biotechnologies that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Collplant Biotechnologies' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Collplant Biotechnologies' value.| Instituion | Recorded On | Shares | |
| Parallel Advisors, Llc | 2023-12-31 | 71.0 |
Collplant Biotechnologies Historical Income Statement
Collplant Biotechnologies Income Statement is one of the three primary financial statements used for reporting Collplant's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Collplant Biotechnologies revenue and expense. Collplant Biotechnologies Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Collplant Biotechnologies' Total Other Income Expense Net is very stable compared to the past year. As of the 25th of April 2024, Total Revenue is likely to grow to about 11.5 M, while Depreciation And Amortization is likely to drop about 878.7 K. View More FundamentalsCollplant Stock Against Markets
Picking the right benchmark for Collplant Biotechnologies stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Collplant Biotechnologies stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Collplant Biotechnologies is critical whether you are bullish or bearish towards Collplant Biotechnologies at a given time. Please also check how Collplant Biotechnologies' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Collplant Biotechnologies without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Money Flow Index Now
Money Flow IndexDetermine momentum by analyzing Money Flow Index and other technical indicators |
| All Next | Launch Module |
Collplant Biotechnologies Corporate Directors
Collplant Biotechnologies corporate directors refer to members of a Collplant Biotechnologies board of directors. The board of directors generally takes responsibility for the Collplant Biotechnologies' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Collplant Biotechnologies' board members must vote for the resolution. The Collplant Biotechnologies board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Abraham Havron | Independent Director | Profile | |
| Adi Goldin | Director | Profile | |
| Elan Penn | External Director | Profile | |
| Talya Zavchon | Finance Director | Profile |
How to buy Collplant Stock?
Before investing in Collplant Biotechnologies, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Collplant Biotechnologies. To buy Collplant Biotechnologies stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Collplant Biotechnologies. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Collplant Biotechnologies stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Collplant Biotechnologies stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Collplant Biotechnologies stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Collplant Biotechnologies, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Collplant Stock please use our How to Invest in Collplant Biotechnologies guide.
Already Invested in Collplant Biotechnologies?
The danger of trading Collplant Biotechnologies is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Collplant Biotechnologies is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Collplant Biotechnologies. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Collplant Biotechnologies is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Collplant Biotechnologies offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Collplant Biotechnologies' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Collplant Biotechnologies Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Collplant Biotechnologies Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Collplant Biotechnologies. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. To learn how to invest in Collplant Stock, please use our How to Invest in Collplant Biotechnologies guide.Note that the Collplant Biotechnologies information on this page should be used as a complementary analysis to other Collplant Biotechnologies' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Complementary Tools for Collplant Stock analysis
When running Collplant Biotechnologies' price analysis, check to measure Collplant Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Collplant Biotechnologies is operating at the current time. Most of Collplant Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Collplant Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Collplant Biotechnologies' price. Additionally, you may evaluate how the addition of Collplant Biotechnologies to your portfolios can decrease your overall portfolio volatility.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |
Is Collplant Biotechnologies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Collplant Biotechnologies. If investors know Collplant will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Collplant Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.62) | Revenue Per Share 0.962 | Quarterly Revenue Growth 4.155 | Return On Assets (0.13) | Return On Equity (0.23) |
The market value of Collplant Biotechnologies is measured differently than its book value, which is the value of Collplant that is recorded on the company's balance sheet. Investors also form their own opinion of Collplant Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Collplant Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Collplant Biotechnologies' market value can be influenced by many factors that don't directly affect Collplant Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Collplant Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Collplant Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Collplant Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.